Company Filing History:
Years Active: 2016-2017
Title: Barry O'Connor: Innovator in Thromboxane Receptor Antagonists
Introduction
Barry O'Connor is a notable inventor based in Dublin, Ireland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of thromboxane receptor antagonists. With a total of four patents to his name, O'Connor's work focuses on innovative compounds that address critical health issues.
Latest Patents
O'Connor's latest patents revolve around thromboxane receptor antagonists. These inventions relate to compounds that function as TP antagonists for treating thrombosis and other cardiovascular, renal, or pulmonary diseases. In some embodiments, the invention provides a compound that includes a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. Additionally, the invention outlines a method of treating thrombosis by administering an antithrombotic compound that preferentially binds to a thromboxane receptor, specifically targeting either the TPalpha or TPbeta receptor subtype.
Career Highlights
Barry O'Connor is affiliated with University College Dublin, where he continues to advance his research and innovation in the pharmaceutical field. His work has garnered attention for its potential impact on treating serious health conditions.
Collaborations
O'Connor collaborates with esteemed colleagues, including B Therese Kinsella and Patrick Guiry, who contribute to his research endeavors.
Conclusion
Barry O'Connor's innovative work in thromboxane receptor antagonists showcases his commitment to advancing medical science. His contributions are vital in the ongoing fight against thrombosis and related diseases.